Home » FDA Orders Halt of Regulus’ Chronic Hepatitis C Trial
FDA Orders Halt of Regulus’ Chronic Hepatitis C Trial
A second report of jaundice during Regulus Therapeutics’ trial evaluating RG-101 for the treatment of chronic hepatitis C virus infection has prompted the FDA to place a clinical hold on the study.
The company said it does not expect the hold to affect the timelines for three ongoing studies assessing the candidate.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May